BioSpace News Archive

Alkermes plc announced that the U.S. Food and Drug Administration has approved LYBALVI™ for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate.

Experienced technical operations and CMC leader brings scientific and strategic expertise in oncology drug development and life cycle management

Sutro Biopharma, Inc. announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt, Germany, related to a patient enrollment achievement in the Phase 1 dose escalation and expansion study of M1231 in adult patients with metastatic solid tumors, including non-small cell lung cancer and esophageal squamous cell carcinoma.

CTI BioPharma Corp. announced that the U.S. Food and Drug Administration has accepted its New Drug Application for pacritinib as a treatment for myelofibrosis patients with severe thrombocytopenia, with the NDA being granted Priority Review.

MYND Life Sciences Inc. a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce the expansion of our intellectual property portfolio to more precisely diagnose and then monitor the treatment regime for patients with Major Depressive Disorder and other diseases of inflammation.

Veeva Systems announced that leaders from Boehringer Ingelheim, GSK, and UCB will be among the featured keynote speakers at the 2021 Veeva Commercial & Medical North America Summit Connect on June 10, 2021.

Provention Bio, Inc., a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, announced management will present at the Jefferies Virtual Healthcare Conference on Thursday, June 3, 2021 at 10:30 AM E.T.

Cardiovascular Systems, Inc., a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, announced that the full line of OrbusNeich® JADE® percutaneous transluminal angioplasty over-the-wire balloon catheters is now available in the U.S.

Unique timsTOF trueSCP revolutionizes quantitative single cell biology research with unbiased, deep single-cell 4D-Proteomics™ to complement scRNA-seq; breakthrough paper by Mann et al. identifies and quantifies >1,400 proteins in single cells

APOLLO-B is the Industry’s Furthest Progressed Randomized, Double-Blind, Placebo-Controlled Pivotal Study of an Investigational TTR Silencer in Hereditary and Wild-type ATTR Amyloidosis with Cardiomyopathy